Tumor PD-L1 expression and Nivolumab efficacy: meta-analysis of phase III randomized clinical trials

Conference paper

Salah Eddine El Herrag, Meghit Boumediene Khaled, Soraya Moulessehoul
13th Oncology Meeting Rabah Ferhat, Arab Medical Association Against Cancer (AMAAC) and Algerian Society Of Training & Research In Oncology (SAFRO), Hotel Sheraton Club des Pins, Alger, 2021 Dec 16

Congress Book

Cite

APA Click to copy
Herrag, S. E. E., Khaled, M. B., & Moulessehoul, S. (2021). Tumor PD-L1 expression and Nivolumab efficacy: meta-analysis of phase III randomized clinical trials. Hotel Sheraton Club des Pins, Alger: Arab Medical Association Against Cancer (AMAAC) and Algerian Society Of Training & Research In Oncology (SAFRO).

Chicago/Turabian Click to copy
Herrag, Salah Eddine El, Meghit Boumediene Khaled, and Soraya Moulessehoul. “Tumor PD-L1 Expression and Nivolumab Efficacy: Meta-Analysis of Phase III Randomized Clinical Trials.” 13th Oncology Meeting Rabah Ferhat. Hotel Sheraton Club des Pins, Alger: Arab Medical Association Against Cancer (AMAAC) and Algerian Society Of Training & Research In Oncology (SAFRO), 2021.

MLA Click to copy
Herrag, Salah Eddine El, et al. Tumor PD-L1 Expression and Nivolumab Efficacy: Meta-Analysis of Phase III Randomized Clinical Trials. Arab Medical Association Against Cancer (AMAAC) and Algerian Society Of Training & Research In Oncology (SAFRO), 2021.

BibTeX Click to copy

@inproceedings{salah2021a,
  title = {Tumor PD-L1 expression and Nivolumab efficacy: meta-analysis of phase III randomized clinical trials},
  year = {2021},
  month = dec,
  day = {16},
  address = {Hotel Sheraton Club des Pins, Alger},
  organization = {Arab Medical Association Against Cancer (AMAAC) and Algerian Society Of Training & Research In Oncology (SAFRO)},
  series = {13th Oncology Meeting Rabah Ferhat},
  author = {Herrag, Salah Eddine El and Khaled, Meghit Boumediene and Moulessehoul, Soraya},
  month_numeric = {12}
}

Abstract
Introduction and aims
Nivolumab is a monoclonal antibody that binds to the PD-1 receptor expressed by activated T-cells activating thus an immune response against tumor cells. We conducted a meta-analysis to investigate the effect of tumor PD-L1 expression on the efficacy of Nivolumab.
Materials and Methods
The meta-analysis was performed in conformity with the PRISMA statement. Phase III randomized clinical trials were identified through a systematic literature search over PubMed, Cochrane, and the clinicaltrials.gov databases up until August 15th, 2019. The included studies provided hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), and odds ratios for objective response rates (ORR). The generic inverse variance method was used for the pooled analysis. The statistical analyses were carried out using the R statistical program (version 3.6).
Results:
13 phase 3 RCT were included with 7371 patients. The trials examined the efficacy of Nivolumab in patients with melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), and gastric cancer (GC) with PD-L1 tumor expression levels < 1%, ≥ 1%, < 5%, ≥ 5%, < 10%, and ≥ 10%. The HRs for OS, among patients with PD-L1 < 1%, were (0.71; 95% CI 0.58 ;0.87) for melanoma, (0.77; 95% CI 0.61; 0.97) for NSCLC, (0.89; 95% CI 0.54; 1.45) for SCCHN, (0.98; 95% CI 0.56; 1.72) for RCC, and (0.76; 95% CI 0.49; 1.18) for GC. Among patients with PD-L1 ≥ 10%, the HRs were (0.65; 95% CI 0.46; 0.92) for melanoma, (0.43; 95% CI 0.31; 0.60) for NSCLC, and (0.56; 95% CI 0.31; 1.01) for SCCHN. Patients with higher tumor PD-L1 levels have benefited the most from Nivolumab, where the OS was longer compared with patients with lower PD-L1.
Keywords: Neoplasms; Nivolumab; PD-L1; meta-analysis.

Poster: Tumor PD-L1 expression and Nivolumab efficacy: meta-analysis of phase III randomized clinical trials